Tickers

1. Composite Trajectory Verdict

Given AGNT's asset-light, cloud-based brokerage model where operating cash flow funds agent commissions, revenue share, stock compensation, dividends, and share repurchases, the cash flow statement carries the most weight for assessing financial trajectory, though earnings and balance sheet trends provide essential context.

Composite Trajectory: Mixed

The annual income statement shows clear deterioration over 2023-2025: revenue grew 11.7% but net loss widened from -$8.97M to -$22.71M and operating cash flow fell 43% from $209.1M to $118.6M. However, the most recent quarterly data (H1 2026 vs H1 2025) shows revenue up 8%, operating loss narrowing from -$12.8M to -$7.1M, and net loss narrowing from -$13.3M to -$7.8M. Cash generation remains weak in both annual and interim periods, declining 38% YoY in FY2025 and 22% YoY in H1 2026. The balance sheet has strengthened consistently: equity rose from $204.9M to $280.9M over the last 18 months, net working capital grew 62% from $82.1M to $133.1M, and total cash plus restricted cash increased 25% from $168.6M to $211.1M.

2. Red Flags

• Profitability diverging from revenue growth: FY2025 revenue rose 4.5% YoY to $4.77B but gross profit fell 2.6% to $333.6M and operating loss widened to -$21.5M from -$19.0M (10-K 2025-12-31, Consolidated Statements of Operations).
• Operating cash flow declining sharply: FY2025 cash from operations dropped 38% to $118.6M from $191.5M; H1 2026 fell 22% to $59.3M from $75.9M (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Statements of Cash Flows).
• Large and persistent GAAP vs. non-GAAP gap: FY2025 net loss of -$22.7M vs. adjusted EBITDA of +$33.2M; H1 2026 net loss of -$7.8M vs. adjusted EBITDA of +$29.8M, driven by $136.6M and $66.1M of stock-based compensation respectively (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Recurring litigation accruals: $34.0M contingency in FY2024, $17.0M paid in FY2025, new $4.3M Tuccori Settlement accrual in H1 2026, with Canadian antitrust and derivative suits still unquantified (10-K 2025-12-31, Note 13; 10-Q 2026-06-30, MD&A).
• Accumulated deficit compounding: Grew from -$68.1M (Dec 2024) to -$121.6M (Dec 2025) to -$145.6M (Jun 2026) despite equity rising from APIC increases (10-K 2025-12-31, Consolidated Statements of Stockholders' Equity; 10-Q 2026-06-30, Condensed Statements of Stockholders' Equity).
• Effective tax rate volatility: Q2 2026 tax expense of $5.0M on $2.3M pre-tax income (217% rate); H1 2026 tax expense of $1.4M on -$6.3M pre-tax loss (-23% rate) (10-Q 2026-06-30, Condensed Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results (2023-2025) show deterioration: revenue increased from $4.27B to $4.77B (+11.7%) but gross margin compressed from 7.5% to 7.0%, operating income swung from +$0.5M to -$21.5M, and net loss widened from -$9.0M to -$22.7M (10-K 2025-12-31, Consolidated Statements of Operations). Commissions and agent-related costs grew faster than revenue (5% vs 4% in FY2025), driven by agent capping and revenue share. In contrast, the most recent comparable interim periods show improvement: H1 2026 revenue rose 8% to $2.46B, gross profit rose 3% to $174.1M, operating loss narrowed 44% to -$7.1M, and net loss narrowed 41% to -$7.8M versus H1 2025 (10-Q 2026-06-30, Condensed Statements of Operations). Q2 2026 alone achieved operating income of $1.6M versus -$2.4M in Q2 2025. The annual and interim trends point in opposite directions.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Both annual and interim operating cash flows show meaningful declines. FY2025 net cash from operations fell 38% to $118.6M from $191.5M in FY2024, which was already down 8% from $209.1M in FY2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows). The FY2025 decline was driven by lower agent equity program participation, increased accounts receivable from December revenue timing, and the first $17.0M litigation settlement payment. H1 2026 operating cash flow decreased 22% to $59.3M from $75.9M in H1 2025, primarily due to litigation contingency payments of $18.0M versus $17.0M in H1 2025 (10-Q 2026-06-30, Condensed Statements of Cash Flows). Free cash flow (operating less investing) was $95.1M in FY2025 and $48.3M in H1 2026, both down year-over-year. Financing outflows moderated in H1 2026 ($16.1M vs $44.8M) due to zero share repurchases versus $29.9M in H1 2025, while dividends continued at $16.1M (10-Q 2026-06-30, Condensed Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

The balance sheet has strengthened across both annual and interim comparisons. Total assets grew from $390.7M (Dec 2024) to $442.5M (Dec 2025) to $539.2M (Jun 2026), driven by cash/restricted cash ($168.6M → $181.5M → $211.1M), accounts receivable ($87.7M → $108.8M → $167.6M), and goodwill ($17.2M → $17.9M → $26.9M from the NextHome acquisition) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). Total equity increased from $204.9M to $242.8M to $280.9M, fueled by APIC growth from stock compensation ($962.8M → $1,105.4M → $1,170.5M) despite the accumulating deficit (10-K 2025-12-31, Consolidated Statements of Stockholders' Equity; 10-Q 2026-06-30, Condensed Statements of Stockholders' Equity). Net working capital rose 28% annually ($82.1M → $105.2M) and 27% in H1 2026 ($105.2M → $133.1M) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). No debt is reported; the litigation contingency liability declined from $34.0M to $17.0M to $3.3M as payments were made (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets).

6. Data Gaps

• Quarterly income statement and cash flow data for Q3 2025, Q4 2025, and Q1 2026 (only annual FY2025 and H1 2026/H1 2025 are fully available)
• Standalone Q2 2026 cash flow statement (only six-month YTD provided in 10-Q)
• Segment-level cash flow breakdowns (North American Realty, International Realty, Other Affiliated Services)
• Detailed composition of "other operating activities" line in cash flow ($2.6M in FY2025, $1.7M in H1 2026)
• Full-year 2026 guidance or quarterly cadence to assess seasonality of the H1 2026 improvement
• Breakdown of agent equity vs. growth incentive stock compensation by segment